A new perspective in the prevention and treatment of antitumor therapy-related cardiotoxicity: Intestinal microecology

• Published in: Biomedicine & pharmacotherapy Vol. 170; p. 115588
• Main Authors: Meng, Chenchen, Wang, Xiaoming, Fan, Lu, Fan, Yajie, Yan, Zhipeng, Wang, Yunjiao, Li, Yanyang, Zhang, Junping, Lv, Shichao
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.01.2024; Elsevier
• Subjects: Antitumor therapy; Cardiotoxicity; Cardiotoxicity - etiology; Cardiotoxicity - prevention & control; Cardiovascular Diseases; Dysbiosis - chemically induced; Dysbiosis - complications; Humans; Intestinal microecology; Intestines; Neoplasms - complications; Neoplasms - drug therapy; FBA; BNP; CTX; LVID; LVEF; MadCAM-1; HR; DP; PBA; LVEDP; MTX; NF-κB; iNOS; LVEDV; LBP; SHR; EF; AMP; AF; IL-1; IEC; MT; DGM; DOX; IL-1β; SCFA; IL-6; IL-10; AP; CVD; ZO-2; ZO-1; IL-18; ROS; TLR4; BCAA; HDAC; dp/dtm; CTLA4, DA, Dark agouti; NADPH; TMAO; NO; MCP-1; ANP; PCNA; LVSP; PKC-δ; Intestinal microecology; CK-MB; LVESV; mRNA; HER-4; FS; HER-2; LPS; LDH; ABX; NLRP3; LVESD; SP; Antitumor therapy; I-FABP; AST; MLCK; PGI2; ICIS; VEGF; CK; SOD; 3-OMG; Cardiotoxicity; FMT; LVEDD; DAO; PD-1 / PD-L1; TNF-α; ALPP; DNA; E/A; TAC; SCFAs; 5-FU
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2023.115588

The continuous development of antitumor therapy has significantly reduced the mortality of patients with malignancies. However, the antitumor-related cardiotoxicity has become the leading cause of long-term mortality in patients with malignancies. Besides, the pathogenesis of antitumor-related cardiotoxicity is still unclear, and practical means of prevention and treatment are lacking in clinical practice. Therefore, the major challenge is how to combat the cardiotoxicity of antitumor therapy effectively. More and more studies have shown that antitumor therapy kills tumor cells while causing damage to sensitive tissues such as the intestinal mucosa, leading to the increased permeability of the intestine and the dysbiosis of intestinal microecology. In addition, the dysbiosis of intestinal microecology contributes to the development and progression of cardiovascular diseases through multiple pathways. Thus, the dysbiosis of intestinal microecology may be a potential mechanism and target for antitumor-related cardiotoxicity. We summarized the characteristics of intestinal microecology disorders induced by antitumor therapy and the association between intestinal microecological dysbiosis and CVD. And on this basis, we hypothesized the potential mechanisms of intestinal microecology mediating the occurrence of antitumor-related cardiotoxicity. Then we reviewed the previous studies targeting intestinal microecology against antitumor-associated cardiotoxicity, aiming to provide a reference for future studies on the occurrence and prevention of antitumor-related cardiotoxicity by intestinal microecology. •Antitumor therapy induces the dysregulation of intestinal microecology.•The dysregulation of intestinal microecology increases the incidence of cardiovascular disease.•The dysregulation of intestinal microecology is a potential mechanism of the antitumor therapy-related cardiotoxicity.•The targeted regulation of intestinal microecology alleviates the antitumor therapy-related cardiotoxicity.